NEWS

NEWS

Total 83

53
Press Release NeoImmuneTech to Present at Upcoming Business Conferences
2022-02-09
52
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 checkpoint inhibitor in High-Risk Skin Cancers
2022-02-07
51
Press Release Preclinical Data on NT-I7 Published in Clinical Cancer Research
2022-01-24
50
Press Release NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference
2022-01-05
49
Press Release NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting
2021-11-22
48
Press Release NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-11-16
47
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2021-11-08
46
Press Release NeoImmuneTech Announces First Patient Dosed in Phase 1b Study of NT-I7 (efineptakin alfa) and Kymriah® (tisagenlecleucel) in Relapsed/Refractory Large B-Cell Lymphoma
2021-10-13
45
Press Release NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting
2021-10-05
44
Press Release NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting
2021-09-03

1 2 3 4 5 >>>